Additional preclinical studies demonstrated the activity of ibrutinib in AML with internal tandem duplication of the juxtamembrane region of the FMS-like tyrosine kinase 3 receptor (FLT3-ITD) [38]. Here, FLT3 is linked to acute myeloid leukemia.